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Abstract. Clinical definitions of melioidosis and inhalation-acquired melioidosis (Burkholderia pseudomallei
infection) are described together with the evidence used to develop these definitions. Such definitions support accurate
public health reporting, preparedness planning for deliberate B. pseudomallei release, design of experimental models,
and categorization of naturally acquired melioidosis.
INTRODUCTION
The purpose of this article is to provide case definitions
of melioidosis (Burkholderia pseudomallei infection) and
describe the evidence on which these are based. There are
two definitions that reflect the purpose for which they may
be used. The first is a simple case definition for use by
clinicians, public health reporting, and epidemiological and
clinical studies. The second is a clinical definition of inhala-
tional melioidosis, which has value for preparedness planning
for deliberate B. pseudomallei release, design of experimental
models, and categorization of routes of infection for naturally
acquired melioidosis.
CASE DEFINITIONS
Definition of melioidosis. Reaching a definite diagnosis of
melioidosis is very straightforward when one or more clinical
specimens are culture-positive for B. pseudomallei. This
organism is not thought to be a member of the normal
microbiota,1 and detecting even a single colony of B.
pseudomallei in any specimen taken from a patient with
clinical features consistent with an infective process should be
interpreted as a clinically significant result. Culture is imper-
fect, however, with one study reporting an estimated diag-
nostic sensitivity of around 60%.2 Only culture-proven cases
are collected by national reporting systems, but having some
guidance in place to support the diagnostic process for
patients with suspected melioidosis who are culture-negative
is of considerable clinical importance. Criteria are proposed
for this patient group in Table 1, which is an adaptation
of criteria reported elsewhere.2 Evidence of exposure to
B. pseudomallei (residence or past travel to endemic area,
known outbreak, or laboratory accident) and the presence of
major risk factors for melioidosis (diabetes mellitus, chronic
renal disease, hazardous alcohol use, chronic pulmonary dis-
ease, thalassemia, steroid therapy, and malignancy) should be
considered alongside these criteria to increase or decrease the
weight of clinical suspicion. Serological evidence of exposure
is not included in this definition, because background sero-
positivity is high in endemic regions and the available sero-
logical tests are poorly standardized.3,4 However, serological
testing may be more specific in returned travelers and after
laboratory exposures outside the endemic area.5 Polymerase
chain reaction (PCR) is being increasingly used for confirma-
tion of identity of bacterial cultures, but assays using detec-
tion of nucleic acid directly from clinical specimens are not
sufficiently validated for routine use. Problems that need to
be overcome include better DNA extraction procedures from
blood, serum, or tissue matrices to increase PCR sensitivity
of blood cultures6–8 and careful selection of probe targets
so that they are specific enough to detect all strains of
B. pseudomallei but not so well-conserved that they detect
B. mallei or other Burkholderia species.9 In the event of a
deliberate release of B. pseudomallei, confirmation based on
a culture-confirmed diagnosis would provide definitive evi-
dence of case burden, but the same problems of imperfect
sensitivity of culture and PCR assays are likely to prevail.
Definition of inhalational melioidosis. The purpose of this
diagnostic subcategory is to provide a more focused definition
for biothreat-related research and assist those organizations
who develop guidelines on emergency response after a delib-
erate release. This definition has five criteria, all of which
must be met.
(1) Development of respiratory symptoms (e.g., cough, breath-
lessness, pleuritic chest pain) in the preceding 4 weeks.
(2) Presence of sepsis, defined as two or more of: body
temperature below 36°C or above 38°C, heart rate
greater than 90 beats/minute, respiratory rate greater
than 20 breaths/minute, and white cell count of less than
4 + 109 or greater than 12 + 109 cells/L or more than
10% band forms (immature white blood cells).
(3) Evidence of alveolar infiltrate on chest radiograph
within 48 hours of admission. In the event that there
are previous radiographic records available for the
individual, the infiltrate should be new (not present on
previous radiographs).
(4) No evidence of percutaneous inoculation injury in an
appropriate setting (contaminated soil, mud, pooled sur-
face water in endemic area, or needle stick injury with
pure culture) and evidence of opportunity for inhalational
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exposure (e.g., recent severe weather event, known
aspiration of surface water, or known exposure to aero-
solized B. pseudomallei).
(5) Isolation of B. pseudomallei from any sterile or non-
sterile body site.
Evidence for each of the criteria. Criterion 1. Melioidosis
pneumonia, as with other bacterial pneumonia, usually pre-
sents with acute respiratory symptoms. Although subacute
presentations similar to tuberculosis are well-described,
chronic melioidosis is found in < 15% of cases.10
Criterion 2. Sepsis syndrome is an adverse systemic
response to an infection that includes fever, rapid heart rate
and respiratory rate, low blood pressure, and abnormal white
blood cell count. Severe sepsis, often used as an inclusion
criterion in clinical trials,11 is the presence of sepsis with
sepsis-related organ dysfunction, and septic shock is defined
as the presence of sepsis with sepsis-related organ dysfunction
and persistent hypotension unresponsive to fluid resuscita-
tion. Sepsis syndrome is a common but not universal manifes-
tation of melioidosis in humans; chronic melioidosis, in
particular, may not be associated with significant systemic
inflammation. In an unpublished study based in Thailand,
sepsis criteria were present in 90% of patients with
melioidosis and 93% of patients that died with melioidosis
(Cheng AC, unpublished data). In a prospective melioidosis
study in Darwin, Australia, 116 of 540 (21%) patients with
melioidosis had septic shock on presentation, and 88 (76%) of
these patients presented with pneumonia and septic shock.12
In a marmoset model of inhalational melioidosis, fever,
leucocytosis, and abnormal liver function were present within
24 hours of exposure to aerosolized B. pseudomallei, with
asthenia and dyspnea most pronounced by 48 hours.13 With
lower inoculating doses (< 10 cfu), the time to clinical symp-
toms was slightly longer. The clinical definition for inhala-
tional melioidosis proposed herein uses the widely accepted
Systemic Inflammatory Response Syndrome (SIRS) consen-
sus criteria to identify the presence of sepsis.14
Criterion 3. Pneumonia is the most common presenting
feature of human melioidosis. Given the route of infection,
the majority of cases with inhalational melioidosis might rea-
sonably be expected to present with pneumonia and clinical
and radiological signs of pulmonary involvement. Nonethe-
less, in a minority of cases, inhalation of B. pseudomallei may
present with sepsis without radiological evidence of pulmo-
nary consolidation. Thus, including the criterion for pulmo-
nary consolidation in the clinical definition of inhalational
melioidosis is likely to result in a higher specificity but lower
sensitivity of the definition. The time to appearance of signs
of pulmonary involvement has also been considered in the
clinical definition. In a primate model of inhalational
melioidosis, the highest bacterial densities were seen in the
lungs at 22 hours after exposure (106 organisms/gram tissue),
with multifocal necrotizing pneumonia evident at this time.13
It is also well-recognized that in patients with pneumonia,
abnormal findings may not be seen on the initial chest X-ray.
Therefore, extending the time for radiological abnormalities
to 48 hours after admission will improve the sensitivity of the
clinical definition of inhalational melioidosis.
Criterion 4. The proportion of naturally acquired
melioidosis cases in which the route of infection is inhalation
(or aspiration) compared with percutaneous inoculation or
ingestion remains entirely unclear.15 Indeed, it has not defin-
itively been shown that humans may acquire melioidosis nat-
urally by the inhalation of aerosols, although cases have been
described after near drowning, during which contaminated
water was aspirated directly into the lungs and may also have
been swallowed. The observation that helicopter crews seemed
to be at increased risk of melioidosis during the Vietnam war
has prompted a hypothesis that inhalation of contaminated
dust may be a route of acquisition of melioidosis.16 Pneumo-
nia is more common in the monsoonal season, with severity
correlating to rainfall in the previous 14 days.17 A recent
case-control study in Thailand found that exposure to rainfall
was associated with melioidosis in residents of endemic areas
(Limmathurotsakul D, personal communication). Small animal
studies have found higher virulence when B. pseudomallei
was administered by inhalation compared with the percutane-
ous route.18,19 More recent work in a marmoset model found
that inhalation of < 10 cfu B. pseudomallei was associated with
lethal infection.13
Criterion 5. Inclusion of culture positivity in the definition
of definite melioidosis is consistent with best clinical practice,
but the available evidence does not provide guidance on
whether microbiological culture relating specifically to the
definition of inhalational melioidosis should be restricted to
respiratory secretions or broadened to other sample types.
B. pseudomallei may rapidly become disseminated, and the
site of culture positivity may not reflect the clinical manifes-
tations of disease. Furthermore, patients with melioidosis
who have respiratory manifestations may not have culture-
positive respiratory secretions. A study conducted in north-
east Thailand of over 700 patients with culture-proven
melioidosis who had at least one sputum culture performed
reported that two-thirds of patients with radiological abnor-
malities had a positive sputum culture but that one-third had
Table 1
Criteria for the diagnosis of naturally acquired melioidosis
Definition
Definite melioidosis One or more clinical samples culture-positive for B. pseudomallei
Probable melioidosis Evidence of one or more abscesses that would be consistent with a diagnosis of melioidosis* but culture
not performed or negative for B. pseudomallei, or culture negative for B. pseudomallei on first presentation
but represented to hospital within 1 month with culture-proven melioidosis
Possible melioidosis Clinically suspected melioidosis improved after treatment with an effective antimicrobial regimen for melioidosis
(ceftazidime/carbapenem drug/amoxicillin-clavulanate) or clinically suspected melioidosis but the patient died
before improvement was observed
Not melioidosis Definite alternative diagnosis for manifestations leading to suspected melioidosis or resolution of clinical features
of suspected melioidosis without treatment with antimicrobial drugs with activity against B. pseudomallei
* Evidence of splenic and/or hepatic abscesses with appearance on ultrasound characteristic for melioidosis (Swiss cheese appearance or small dispersed abscesses) or parotid or prostatic abscess
in a melioidosis-endemic region where B. pseudomallei is the most probable cause.
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a sputum culture that was negative.20 Possible explanations
include poor-quality sputum leading to a false-negative sam-
ple, a radiological abnormality associated with miliary spread
(akin to miliary tuberculosis), and radiological changes caused
by acute respiratory distress syndrome. In the same study, one-
half of patients with a negative sputum culture but radiological
changes had a throat swab taken, which was positive in 34% of
cases.20 This result provides evidence that sputum culture may
be falsely negative. Limiting culture positivity to respiratory
secretions in the clinical definition of inhalational melioidosis
would increase specificity and may be suitable for the design
of experimental models and studies that define the relation-
ship between infection route and clinical manifestations of
melioidosis. In the event of a deliberate release associated with
inhalation of B. pseudomallei, it is likely that culture of the
respiratory tract would be positive, but the knowledge that
false-negative sputum culture could occur has influenced
the decision to extend the definition to culture positivity of
any site in this situation. Early inhalational melioidosis may
not be associated with sputum production, and throat swabs
should be taken in all suspected cases together with blood
and urine cultures.
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